Virax Biolabs GroupVRAX
13F holders, Q4 2025 (December 31)5holders +1
3new positions
2sold out
$0.35avg. 13F price*
At the end of Q4 2025, 5 institutions reported holding Virax Biolabs Group Ltd. (VRAX) in their 13F filings, up 1 from Q3 2025. 3 opened new positions and 2 sold out. The largest holders were XTX Topco Ltd ($7K), UBS Group AG ($3K) and National Bank of Canada ($2K).
- Company
- Virax Biolabs Group Ltd.
- CUSIP
- G9495L125
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $7K |
| Exits | 2 | $49K |
All 13F filers, Q3 2025 → Q4 2025: 25,599 shares bought and 85,449 shares sold, net −59,850 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 5 holders
| XTX Topco Ltd | 0.00% | New | 21,437 | $7K |
| UBS Group AG | 0.00% | Add +123.0% | 7,492 | $3K |
| National Bank of Canada | 0.00% | Reduce -40.0% | 6,000 | $2K |
| Osaic Holdings, Inc. | 0.00% | New | 20 | $7 |
| Northwestern Mutual Wealth Management Co. | 0.00% | New | 10 | $3 |
"% of holder's portfolio" is VRAX's weight in each manager's 13F, not the share of Virax Biolabs Group Ltd. the manager owns.